The latest price target for NovaBay Pharmaceuticals (AMEX:NBY) was reported by Ascendiant Capital on November 11, 2024. The analyst firm set a price target for $0.85 expecting NBY to rise to within 12 months (a possible 24.82% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for NovaBay Pharmaceuticals (AMEX:NBY) was provided by Ascendiant Capital, and NovaBay Pharmaceuticals maintained their buy rating.

There is no last upgrade for NovaBay Pharmaceuticals

There is no last downgrade for NovaBay Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovaBay Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovaBay Pharmaceuticals was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest NovaBay Pharmaceuticals (NBY) rating was a maintained with a price target of $8.00 to $0.85. The current price NovaBay Pharmaceuticals (NBY) is trading at is $0.68, which is out of the analyst’s predicted range.